Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

被引：0
|
作者：
Chunnan Liu
Zhaopei Liu
Kaifeng Jin
Han Zeng
Fei Shao
Yuan Chang
Yiwei Wang
Le Xu
Zewei Wang
Yu Zhu
Weijuan Zhang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Urology
[2] Fudan University,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences
[3] Fudan University,Department of Urology, Zhongshan Hospital
[4] Shanghai Jiao Tong University School of Medicine,Department of Oncology, Shanghai General Hospital
[5] Shanghai Jiao Tong University School of Medicine,Department of Urology, Shanghai Ninth People’s Hospital
[6] Shanghai Jiao Tong University School of Medicine,Department of Urology, Ruijin Hospital
[7] Fudan University,Department of Immunology, School of Basic Medical Sciences
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1718 / 1725
页数：7
相关论文
共 50 条
  • [31] Drug response to PD-1/PD-L1 blockade: based on biomarkers
    Chen, Qi
    Li, Tianhe
    Yue, Wentao
    ONCOTARGETS AND THERAPY, 2018, 11 : 4673 - 4683
  • [32] Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
    Shin, Kabsoo
    Kim, Joori
    Park, Se Jun
    Lee, Myung Ah
    Park, Jae Myung
    Choi, Myung-Gyu
    Kang, Donghoon
    Song, Kyo Young
    Lee, Han Hong
    Seo, Ho Seok
    Lee, Sung Hak
    Kim, Bohyun
    Kim, Okran
    Park, Juyeon
    Kang, Nahyeon
    Kim, In-Ho
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
    Kabsoo Shin
    Joori Kim
    Se Jun Park
    Myung Ah Lee
    Jae Myung Park
    Myung-Gyu Choi
    Donghoon Kang
    Kyo Young Song
    Han Hong Lee
    Ho Seok Seo
    Sung Hak Lee
    Bohyun Kim
    Okran Kim
    Juyeon Park
    Nahyeon Kang
    In-Ho Kim
    Scientific Reports, 13
  • [34] CD57+CD8+T cells and response to PD-1/PD-L1 blockade in patients with NSCLC
    Zhou, Jianya
    Sun, Wenjia
    Zeng, Xun
    Zheng, Jing
    Qu, Jingjing
    Jiang, Nan
    Zhou, Jianying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] New strategies with PD-1/PD-L1 blockade in lung cancer
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (SUPPL 3) : 54 - 58
  • [36] PD-L1/PD-1 blockade in breast cancer: The immunotherapy era
    Li, Chia-Jung
    Lin, Li-Te
    Hou, Ming-Feng
    Chu, Pei-Yi
    ONCOLOGY REPORTS, 2021, 45 (01) : 5 - 12
  • [37] PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
    Yaghoubi, Neda
    Soltani, Arash
    Ghazvini, Kiarash
    Hassanian, Seyed Mahdi
    Hashemy, Seyed Isaac
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 110 : 312 - 318
  • [38] PD-L1 X CTLA-4 IN INVASIVE BLADDER CANCER
    Pereira, Fabiana
    Mattos, Tatiana
    Silva, Maria Antonieta
    Martini Filho, Dino
    Fernandes, Roni
    Toledo, Luis Gustavo
    Leitao, Luiz Felipe
    Montor, Wagner
    JOURNAL OF UROLOGY, 2021, 206 : E999 - E999
  • [39] PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
    Hosseinzadeh, Ramin
    Feizisani, Fahimeh
    Shomali, Navid
    Abdelbasset, Walid Kamal
    Hemmatzadeh, Maryam
    Gholizadeh Navashenaq, Jamshid
    Jadidi-Niaragh, Farhad
    Bokov, Dmitry O.
    Janebifam, Morteza
    Mohammadi, Hamed
    IUBMB LIFE, 2021, 73 (11) : 1293 - 1306
  • [40] Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Shergold, Amy L.
    Millar, Rhona
    Nibbs, Robert J. B.
    PHARMACOLOGICAL RESEARCH, 2019, 145
12345